Currently, the common chemotherapy regimen for gastrointestinal tract tumors is FOLFOX regimen, which has the following 2 different dosing methods: 1. mFOLFOX6 regimen dosing schedule: Oxaliplatin: 2 hours intravenous infusion, day 1; Tetrahydrofolate: 2 hours intravenous infusion, day 1; 5-Fu: 44-46 hours continuous intravenous infusion. The first chemotherapy is feasible after the patient’s postoperative outpatient review and assessment at 3-4 weeks, and if there is no specific significant discomfort, the chemotherapy will be regular thereafter according to this protocol. It is recommended to repeat every 2 weeks for a total of 12 chemotherapy sessions. 2, FOLFOX regimen dosing schedule: oxaliplatin: intravenous drip 2 hours, day 1; tetrahydrofolic acid: intravenous drip 2 hours, days 1-5; 5-Fu: intravenous drip 2 hours, days 1-5; the first chemotherapy is feasible after the patient’s postoperative outpatient review and assessment 3-4 weeks, if there is no special obvious discomfort, thereafter regular chemotherapy according to this regimen. It is recommended to repeat every 4 weeks for a total of 6 times of chemotherapy. 3.Discharge procedure: Patients should start chemotherapy on the date of the last chemotherapy, and then move backward 2 or 4 weeks, which is the preliminary estimate of the next chemotherapy start date. Four days before this date, review your blood work and make an appointment for hospitalization. The ward physician will try to schedule your admission to chemotherapy on time. On the day of admission, patients should check in on an empty stomach. If the results are normal, chemotherapy will be administered in the afternoon of the day of hospitalization. On the first day of chemotherapy, the principle of inpatient observation should be strictly observed, and patients should not take leave to go home. After the end of intravenous treatment on the 1st day of chemotherapy, the patient will be given chemotherapy drugs pumped continuously for 44-46 hours, and after the 5-Fu solution is completely pumped, the blood routine and liver and kidney function should be rechecked and further treated according to the results. The FOLFOX4 regimen is chosen and requires a 5-day hospital stay. Blood tests and liver and kidney function will be repeated after the end of the drip on day 5, and if the results are normal, the patient will be discharged on the same day or on day 2. If the patient’s blood test results are significantly abnormal on the day of admission, such as a significant decrease in white blood cells or an increase in transaminases, whitening therapy or liver-protective therapy will be required. The chemotherapy will be started only after the results of white blood cell and liver function are normalized after treatment. 4.Out-of-hospital precautions: Since most of the adverse reactions reported by oxaliplatin are myelosuppression, gastrointestinal reactions and neurotoxic reactions, and most of the 5-Fu adverse reactions are gastrointestinal reactions, patients should pay close attention to the changes in their condition during the chemotherapy interval outside the hospital, and seek medical attention promptly if there are any abnormalities. (1) Bone marrow suppression: Patients should pay close attention to the fluctuation of white blood cells during the chemotherapy interval. It is recommended that patients should have their blood count rechecked every 3 to 4 days after discharge. If leukocytes are found to be lower than 4.0X109/L or neutrophils lower than 1.5X109/L, whitening treatment should be given. (2) Gastrointestinal reactions: Patients may experience gastrointestinal reactions such as nausea and vomiting during chemotherapy, so see the patient for a regular and light diet during chemotherapy to prevent nausea and vomiting and other uncomfortable symptoms. In case of severe vomiting, patients should be promptly treated with rehydration. (3) Neurotoxic reactions: The main manifestations are sensory impairment or/and abnormal sensation at the end of the limbs. With or without painful spasms, this symptom is usually triggered by cold. The incidence of neurotoxicity due to oxaliplatin has been reported to be 85-95%. Symptoms usually diminish during intervals of treatment, but progressively worsen with increasing treatment cycles. If symptoms are severe and prolonged, they should be reported to the physician at the time of the next chemotherapy treatment. The physician will decide to reduce or suspend oxaliplatin depending on the patient’s specific situation.